Intersect ENT, Inc.

Intersect ENT, Inc.

Intersect ENT, Inc.

Overview
Date Founded

2003

Headquarters

1555 Adams Drive,Menlo Park, CA 94025

Type of Company

Public

Employees (Worldwide)

406

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Medical Products & Equipment

Company Description

Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.

Contact Data
Trying to get in touch with decision makers at Intersect ENT, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Director, President & Chief Executive Officer

Executive Vice President & Chief Financial Officer

Secretary, Executive Vice President & General Counsel

Chief Human Resources Officer

Vice President, Regulatory Affairs

Vice President, Global Market Access

Vice President, Healthcare Economics & Reimbursement

Owner

Head-Media Relations

Director Research & Development

Board of Directors

Former Chairman at Intersect ENT, Inc.

Member-Deans Council at Indiana University - Kelley School of Business

Former Sales & Marketing at Johnson & Johnson

Advisor at Healthwell Acquisition Corp. I

Director, President & Chief Executive Officer at Intersect ENT, Inc.

President & Chief Operating Officer at Spirox, Inc.

Former Vice President of Global Marketing & Strategy at Bausch + Lomb, Inc.

Paths to Intersect ENT, Inc.
Potential Connections via
Relationship Science
You
Intersect ENT, Inc.
Owners & Shareholders
Details Hidden

Magnetar Financial implements a variety of different strategies in managing private investment funds and separately managed accounts (SMAs) which designed to achieve attractive risk-adjusted rates of return. Some of the funds and SMAs employ a multi-strategy approach, utilizing a wide range of strategies across a range of geographies, while others focus on one or just a few strategies. It may hold both long and short positions in a broad range of securities, derivatives, and other assets. In executing their investment strategies, the funds and SMAs may enter into joint venture or co-investment arrangements, participate in pooled investment vehicles, invest with affiliated or unaffiliated advisors or managers, or make direct investments in operating entities. The firm’s main investment strategies are divided into the following categories: relative-value, event-driven, directional, hybrid and other investment strategies.

Details Hidden

First Light manages a long-only health care equity investment strategy (the Genesis Strategy) for separate account clients. The Genesis Strategy utilizes a fundamental, bottom-up approach to stock selection in an attempt to primarily seek out high quality, reasonably priced, growth-equity opportunities among publicly-traded micro to small/mid-cap health care and life sciences companies. It targets companies developing transformative devices, technologies and innovations that may save money and/or improve patient care.

Details Hidden

Versor creates diversified sources of absolute returns across multiple asset classes. The firm offers two categories of investment products – Hedge Funds and Alternative Risk Premia. Both are designed to provide superior risk-adjusted returns while exhibiting low correlation to traditional and alternative asset classes. Each invests in liquid, scalable markets.

Recent Transactions
Details Hidden

Medtronic Plc purchases Intersect ENT, Inc.

Details Hidden

Intersect ENT, Inc. issued USD Common Stock

Details Hidden

Intersect ENT, Inc. issued USD Common Stock

Transaction Advisors
Underwriter

Advised onIntersect ENT, Inc. issued USD Common Stock

Underwriter

Advised onIntersect ENT, Inc. issued USD Common Stock

Underwriter

Advised onIntersect ENT, Inc. issued USD Common Stock

Associate

Advised onIntersect ENT, Inc. issued USD Common Stock

Legal Advisor

Advised onIntersect ENT, Inc. issued USD Common Stock

Associate

Advised onIntersect ENT, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner, Palo Alto at Cooley LLP

Advisor

Assurance Partner at Ernst & Young LLP

Legal Advisor

Partner, Palo Alto at Cooley LLP

Clients

TO PROVIDE PATIENT CARE AT THE HIGHEST QUALITY, MOST TECHNOLOGICALLY ADVANCED AND CONSISTENT MULTIDISCIPLINARY CARE.

Key Stats and Financials As of 2020
Market Capitalization
$909M
Total Enterprise Value
$741M
Earnings Per Share
$-2.22
Revenue
$80.6M
Total Equity
$67M
Net Profit
$-72.3M
EBITDAMargin
-68.88%
Enterprise Value / Sales
9.2x
TEVNet Income
-10.25x
Debt TEV
0.11x
Total Debt
$82.1M
EBITDA
$-55.5M
Three Year Compounded Annual Growth Rate Of Revenue
-5.78%
Investors
Details Hidden

Presidio Management Group seeks investment opportunities in companies located in US. The firm targets companies operating in the fields of cyber security, enterprise software, consumer and healthcare. It provides financing for early stage capital requirements.

Details Hidden

Kleiner Perkins Caufield & Byers invests in companies located in the United States. The firm targets companies operating in consumer, enterprise, hardtech and healthcare sectors. It provides financing for seed, early, and later stage capital requirements.

Details Hidden

Founder at Intersect ENT, Inc.

Suppliers
Hovione Farmaciência SA Wholesale: Consumer Non-Durables/Sundries | Loures, Portugal

Hovione FarmaCiencia SA manufactures and distributes active pharmaceutical ingredients. Its services include contract manufacturing services, off-patent API products, proprietary product licensing, and supporting capabilities. The company was founded by Diane de Lancastre Houssemayne Du Boulay Villax, Ivan Villax, Nicholas de Horthy and Andrew Onody in 1959 and is headquartered in Loures, Portugal.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $82.6 billion during calendar year 2020. Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. Johnson & Johnson's pharmaceutical arm is Janssen Pharmaceutica.

Medtronic Plc Medical Products & Equipment - Dublin, Irl

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consists of products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Minimally Invasive Technologies Group segment focuses on respiratory system, gastrointestinal tract, renal system, lungs, pelvic region, kidneys, and obesity diseases. The Restorative Therapies Group segment comprises of neurostimulation therapies and drug delivery systems for the treatment of chronic pain, as well as areas of the spine and brain, along with pelvic health and conditions of the ear, nose, and throat. The Diabetes Group segment offers insulin pumps, coninuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Awards & Honors
Rank #39
2014
Forbes - America's Most Promising Companies
Sponsored by Forbes Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Intersect ENT, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Intersect ENT, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Intersect ENT, Inc..